Vireo Growth (VREOF) EBIT Growth (3y) (2023 - 2026)
Vireo Growth (VREOF) EBIT Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 29.31% |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 4.24% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 0.90% |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 1.82% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -74.25% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 27.21% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 35.42% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Vireo Growth | 491.44 Mn | 349.14 Mn | 95.30 Mn | -82.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 190.13% |
| Dec 31, 2025 | -66.14% |
| Sep 30, 2025 | 84.46% |
| Jun 30, 2025 | -104.48% |
| Mar 31, 2025 | 31.19% |
| Dec 31, 2024 | 53.29% |
| Sep 30, 2024 | 43.13% |
| Jun 30, 2024 | 55.83% |
| Mar 31, 2024 | 43.94% |
| Dec 31, 2023 | 64.04% |
| Sep 30, 2023 | 66.16% |
| Jun 30, 2023 | 55.78% |
| Mar 31, 2023 | 27.17% |